Not every patient who wishes to lose weight is automatically a candidate for GLP-1 receptor agonist medications. The FDA has established specific eligibility criteria for Wegovy and Zepbound based on body mass index (BMI) and the presence of certain weight-related medical conditions. Additionally, there are important contraindications and precautions that must be evaluated before initiating therapy. This article provides a comprehensive overview of who qualifies for these medications, what medical evaluation is required, and what conditions may preclude their use.
FDA-Approved Eligibility Criteria
The FDA approval for both Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) for chronic weight management specifies the following patient selection criteria:
- BMI ≥ 30 kg/m² (obesity): Adults with a BMI at or above this threshold qualify for treatment regardless of the presence or absence of weight-related comorbidities. Obesity at this level is recognized as a disease state in itself that carries independent health risks including cardiovascular disease, certain cancers, sleep apnea, and reduced life expectancy.
- BMI ≥ 27 kg/m² (overweight) WITH at least one weight-related comorbidity: Adults in the overweight range who have one or more of the following comorbid conditions qualify:
- Type 2 diabetes mellitus
- Hypertension (elevated blood pressure)
- Dyslipidemia (abnormal blood lipid levels, e.g., high LDL, low HDL, elevated triglycerides)
- Obstructive sleep apnea
- Cardiovascular disease (coronary artery disease, history of myocardial infarction or stroke, peripheral arterial disease)
Both medications are approved as adjuncts to a reduced-calorie diet and increased physical activity — meaning they are intended to be used alongside lifestyle modification, not as replacements for it. Patients who are not willing or able to make any dietary or activity changes are less likely to derive full benefit.
What BMI Actually Measures — and Its Limitations
BMI is calculated as weight in kilograms divided by height in meters squared (kg/m²). It is a population-level screening tool that correlates with body fatness and health risk at the group level but has important limitations in clinical practice:
- BMI does not distinguish between fat mass and muscle mass — highly muscular individuals may have elevated BMI without excess adiposity.
- BMI does not measure body fat distribution — visceral (abdominal) fat is more metabolically harmful than subcutaneous fat, and waist circumference is a complementary metric.
- BMI thresholds were derived from predominantly European populations; professional societies including the American Diabetes Association recommend considering lower BMI thresholds for risk classification in Asian populations.
Despite these limitations, BMI remains the primary FDA eligibility criterion for GLP-1 RA prescribing and is the metric used in insurance prior authorization criteria.
💡 💡 Clinical Pearl
Some professional obesity societies, including the American Association of Clinical Endocrinology (AACE) and the Obesity Society, advocate for a more comprehensive assessment that goes beyond BMI alone. They propose diagnosing and treating "adiposity-based chronic disease" (ABCD) — a framework that considers the degree of adiposity, the presence of obesity-related complications, and the functional impact of excess weight. Under this model, a patient with a BMI of 26 kg/m² who has severe type 2 diabetes and cardiovascular disease may clinically warrant pharmacotherapy even if they fall just below the current FDA BMI threshold. Discuss individual circumstances with a physician who specializes in obesity medicine.
Absolute Contraindications
Certain patient populations must not use Wegovy or Zepbound due to known or potential serious harms:
- Personal or family history of medullary thyroid carcinoma (MTC): Both semaglutide and tirzepatide carry a boxed warning for thyroid C-cell tumor risk based on rodent studies. While a causal link in humans has not been established, these medications are contraindicated in anyone with a personal or family history of MTC.
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): This hereditary syndrome predisposes to medullary thyroid carcinoma and is an absolute contraindication.
- Serious hypersensitivity reaction to semaglutide, tirzepatide, or any excipient in their formulations (e.g., anaphylaxis, angioedema).
- Pregnancy: Weight loss is not recommended during pregnancy. GLP-1 RAs should be discontinued at least 2 months (semaglutide) before a planned pregnancy due to the long half-life and unknown effects on fetal development.
Conditions Requiring Caution or Closer Monitoring
The following conditions are not absolute contraindications but warrant careful clinical assessment before and during GLP-1 RA therapy:
- History of pancreatitis: GLP-1 RAs have been associated with acute pancreatitis. While the causal relationship remains debated, patients with a history of pancreatitis or known risk factors (gallstones, hypertriglyceridemia, alcohol use) should have individual risk-benefit discussions with their physician.
- Gastroparesis or severe gastrointestinal disease: GLP-1 RAs slow gastric emptying and may exacerbate pre-existing gastroparesis, causing unpredictable drug absorption and worsening GI symptoms.
- Diabetic retinopathy: Rapid improvement in blood glucose control has been associated with a temporary increase in diabetic retinopathy complications. Patients with known diabetic retinopathy should have ophthalmic monitoring.
- Renal impairment: No dose adjustment is required for GLP-1 RAs in chronic kidney disease, but dehydration from GI side effects can worsen renal function. Monitor closely in patients with CKD.
- Type 1 diabetes: GLP-1 RAs are not approved for type 1 diabetes and should not be used as insulin replacements in this population.
What Medical Evaluation Is Needed Before Starting?
Before initiating GLP-1 RA therapy for weight management, a physician will typically conduct or review:
- Measurement and documentation of current BMI, weight, and waist circumference
- Assessment of weight-related comorbidities (blood pressure, fasting blood glucose or HbA1c, fasting lipid panel)
- Personal and family history for thyroid carcinoma and MEN 2
- Current medication list — particularly insulin and sulfonylureas (hypoglycemia risk) and oral contraceptives (potential absorption changes with delayed gastric emptying)
- Discussion of the chronic nature of obesity and the expectation that treatment will likely be long-term
- Informed consent regarding the boxed warnings, common side effects, and need for titration
For information about how different medications are approved for different indications, see GLP-1 RA for Type 2 Diabetes vs. Obesity: Understanding the Difference. For the clinical trial evidence supporting these approvals, see The Science Behind the Weight Loss Numbers.
💡 Frequently Asked Questions (FAQ)
Q1: My BMI is 26 — can I still get Wegovy if I am concerned about my weight?
A1: Based on current FDA labeling, a BMI of 26 kg/m² does not meet the eligibility threshold of ≥27 kg/m² with a comorbidity or ≥30 kg/m² without. Insurance coverage would almost certainly be denied. However, clinical practice is evolving, and some physicians may consider treatment in borderline cases with compelling clinical circumstances. A comprehensive obesity medicine consultation is the best path forward for patients in this situation.
Q2: Do I need to try diet and exercise first before being approved for GLP-1 RAs?
A2: Many insurance plans require documented evidence of prior dietary and lifestyle intervention (typically 3–6 months) before approving coverage for weight management medications. The FDA labels do not mandate this for clinical prescribing, but insurance prior authorization criteria often do. Your prescriber’s office can advise on the documentation requirements for your specific insurance plan.
Q3: I had my gallbladder removed — can I still use Wegovy?
A3: Prior cholecystectomy (gallbladder removal) is not a contraindication to GLP-1 RA therapy. Rapid weight loss associated with any weight management intervention (including GLP-1 RAs) can increase the risk of developing new gallstones in people who still have a gallbladder, but having already had the gallbladder removed eliminates this specific risk.
📚 References & Sources
- FDA. (2021). Prescribing Information: Wegovy (semaglutide) injection 2.4 mg. U.S. Food and Drug Administration.
- American Diabetes Association. (2024). Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes. Diabetes Care, 47(Suppl.1).
- Jastreboff, A.M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.